Supplemental material
OncoImmunology
Volume 7, 2018 - Issue 12
Original Research
Long-peptide vaccination with driver gene mutations in p53 and Kras induces cancer mutation-specific effector as well as regulatory T cell responses
, , 
, , , , , , , , & show all
Michael BartoschekDepartment of Translational Immunology, German Cancer Research Center (DKFZ) and National Center for Tumor Diseases (NCT), Heidelberg, Germany;Division of Translational Cancer Research, Department of Laboratory Medicine, Lund University, Lund, Swedenhttp://orcid.org/0000-0002-1567-795X
http://orcid.org/0000-0002-1567-795X, , , Sebastian SchölchDepartment of Visceral Surgery, University Hospital Heidelberg, Heidelberg, Germany;Department of Surgery, Universitätsmedizin Mannheim, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germanyhttp://orcid.org/0000-0003-0012-3177
http://orcid.org/0000-0003-0012-3177, , , , Stefan WiemannGenomics and Proteomics Core Facility, German Cancer Research Center (DKFZ), Heidelberg, Germany;Division Molecular Genome Analysis, German Cancer Research Center (DKFZ), Heidelberg, Germanyhttp://orcid.org/0000-0003-4683-3174
http://orcid.org/0000-0003-4683-3174, & show allRelated Research Data
Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines.
Source:
Rockefeller University Press
Cancer vaccines: should we be targeting patients with less aggressive disease?
Source:
Informa UK Limited
HLA Class II tetramers reveal tissue-specific regulatory T cells that suppress T-cell responses in breast carcinoma patients.
Source:
Informa UK Limited
A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma
Source:
American Association for the Advancement of Science (AAAS)
Identification of Novel HLA Class II-Restricted Neoantigens Derived from Driver Mutations.
Source:
MDPI AG
The immunological and clinical effects of mutated ras peptide vaccine in combination with IL-2, GM-CSF, or both in patients with solid tumors
Source:
Springer Nature
A new era in anticancer peptide vaccines
Source:
Wiley
Melanoma-reactive T cells in the bone marrow of melanoma patients: association with disease stage and disease duration.
Source:
American Association for Cancer Research (AACR)
Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival
Source:
Springer Science and Business Media LLC
Mechanisms of peptide vaccination in mouse models: tolerance, immunity, and hyperreactivity.
Source:
Elsevier
CD8+ CTL Priming by Exact Peptide Epitopes in Incomplete Freund’s Adjuvant Induces a Vanishing CTL Response, whereas Long Peptides Induce Sustained CTL Reactivity
Source:
The American Association of Immunologists
MUC1 immunobiology: from discovery to clinical applications.
Source:
Elsevier
Response determination criteria for ELISPOT: toward a standard that can be applied across laboratories.
Source:
Humana Press
Pancreatic cancer biology and genetics
Source:
Springer Science and Business Media LLC
Changes in Paracrine Interleukin-2 Requirement, CCR7 Expression, Frequency, and Cytokine Secretion of Human Immunodeficiency Virus-Specific CD4+ T Cells Are a Consequence of Antigen Load
Source:
American Society for Microbiology
Vaccination against HPV-16 Oncoproteins for Vulvar Intraepithelial Neoplasia
Source:
Massachusetts Medical Society
Tumor-specific cytotoxic T lymphocyte activity determines colorectal cancer patient prognosis
Source:
American Society for Clinical Investigation
Long-term follow-up of patients with resected pancreatic cancer following vaccination against mutant K-ras.
Source:
Wiley
Self-Tolerance Does Not Restrict the CD4+ T-Helper Response against the p53 Tumor Antigen
Source:
American Association for Cancer Research (AACR)
Biological properties of human c-Ha-ras1 genes mutated at codon 12
Source:
Springer Science and Business Media LLC
A vaccine targeting mutant IDH1 induces antitumour immunity
Source:
Springer Science and Business Media LLC
Cross-priming in health and disease.
Source:
Springer Science and Business Media LLC
Immunization with mutant p53- and K-ras-derived peptides in cancer patients: Immune response and clinical outcome
Source:
American Society of Clinical Oncology (ASCO)
A mouse model of human adaptive immune functions: HLA-A2.1-/HLA-DR1-transgenic H-2 class I-/class II-knockout mice.
Source:
Wiley
Immunotherapy of established (pre)malignant disease by synthetic long peptide vaccines
Source:
Springer Science and Business Media LLC
Cancer Genome Landscapes
Source:
American Association for the Advancement of Science (AAAS)
Mutations in the KRAS2 oncogene during progressive stages of human colon carcinoma.
Source:
Proceedings of the National Academy of Sciences
HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T-cells
Source:
American Society of Hematology
Mutant MHC class II epitopes drive therapeutic immune responses to cancer
Source:
Springer Science and Business Media LLC
NY-ESO-1: review of an immunogenic tumor antigen.
Source:
Elsevier
Antigen-induced regulatory T cells in autoimmunity
Source:
Springer Science and Business Media LLC
The Frequency of High Avidity T Cells Determines the Hierarchy of Determinant Spreading
Source:
The American Association of Immunologists
Role of oncogenic KRAS in the diagnosis, prognosis and treatment of pancreatic cancer.
Source:
Springer Science and Business Media LLC
IDENTIFICATION OF OVERLAPPING EPITOPES IN MUTANT RAS ONCOGENE PEPTIDES THAT ACTIVATE CD4+ AND CD8+ T CELL RESPONSES
Source:
Wiley
HLA-A3 restricted mutant ras specific cytotoxic T-lymphocytes induced by vaccination with T-helper epitopes.
Source:
Springer Science and Business Media LLC
Linking provided by
